besylate

Amlodipine Besylate(Amlodipine benzenesulfonate) is a long-lasting calcium channel blocker.

Cisatracurium besylate (51W89) is a nondepolarizing skeletal muscle relaxant intended for intravenous administration.

Levamlodipine besylate ((S)-Amlodipine Besylate (103129-82-4(free base))) , also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive and anti-anginal medication. Levamlodipine besylate belongs to the dihydropyridine group of calcium channel blockers. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however, with differing nomenclature. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.

Atracurium besylate (51W89) is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.

PF-562271 besylate (PF-00562271 Besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

Amlodipine besylate monohydrate is a medication used to lower blood pressure and prevent chest pain.

BPN-15606 besylate is a highly potent, orally active γ-secretase modulator, attenuates the production of Aβ40 and Aβ42 by SHSY5Y neuroblastoma cells (IC50s: 7 nM and 17nM).

Gisadenafil besylate (UK 369003-26) is a potent and orally active PDE5 inhibitor (IC50=1.23 nM), 100 times more selective for PDE5 than PDE6, for the study of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Molibresib besylate (GSK 525762C) is a selective and potent inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential anticancer activity for the study of refractory hematologic malignant diseases.Molibresib besylate generates reactive oxygen species (ROS), which potentiate ATM activation.

Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor with an IC50 of less than 0.5 nM and a Kinact Ki of 7.69×10^4 M^-1s^-1.

Levamlodipine besylate hemipentahydrate is the besylate hemipentahydrate salt form of Levamlodipine. It is an orally effective calcium channel blocker with antioxidative and vasodilatory properties. This compound can reduce serum malondialdehyde (MDA) levels, enhance the activity of superoxide dismutase (SOD), and alleviate oxidative stress. Levamlodipine besylate hemipentahydrate is relevant for research in vascular dementia, hypertension, and cerebrovascular diseases.

Amlodipine besylate, (R)- is a medication used to lower blood pressure and prevent chest pain.

Mesoridazine Besylate (Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine.

Epelsiban Besylate is an oral drug that is a highly selective anamol oxytocin receptor antagonist.

Mirogabalin besylate is a potent and orally active ligand that selectively targets the α2δ subunit of voltage-gated calcium channels. It displays high affinity (K d ) values, namely 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM, for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively.

BPN-15606 besylate is a potent, orally active γ-secretase regulator (GSM) that reduces the production of Aβ42 (IC50: 7 nM) and Aβ40 (IC50: 17 nM) by SHSY5Y neuroblastoma cells. BPN-15606 besylate exhibited good PK PD properties (including bioavailability, half-life and clearance).

Crenolanib besylate is a useful organic compound for research related to life sciences and the catalog number is T64425.

AG-28262 besylate is a VEGFR-2 Inhibitorwhich may affect alanine aminotransferase gene expression and enzymatic activity in the liver.

AMG-131 besylate is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.

MK-0359 besylate is a Phosphodiesterase-4 (PDE4) inhibitor.

(R)-Azasetron besylate (SENS-401), an orally active calcineurin inhibitor, has been demonstrated to mitigate cisplatin-induced hearing loss and cochlear damage [1][2].

Avanafil dibesylate is a PDE5 inhibitor.

R406 (R-406 besylate) is an effective Syk inhibitor (IC50: 41 nM) and shows no effects on Lyn.

AG28262 is a VEFG-2 inhibitor that increases serum ALT, due in part to both gene up-regulation.